Table 3.
Baseline and 3-month and 6-month tocilizumab therapy criteria in 13 patients with axial spondyloarthritis
| Pt 1 | Pt 2 | Pt 3 | Pt 4 | Pt 5 | Pt 6 | Pt 7 | Pt 8 | Pt 9 | Pt 10 | Pt 11 | Pt 12 | Pt 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BASDAI, 0 to 100 | |||||||||||||
| M0 | 78 | 90 | 72 | 42 | 77 | 63 | 80 | 48 | 49 | 59 | 48 | 72 | 57 |
| M3 (change from M0; %) | +6 | -19 | +1 | -15 | +1 | -1.6 | +3.8 | -2 | +4 | -5 | +43 | -10 | -12 |
| M6 (change from M0; %) | NA | NA | NA | -17 | NA | NA | NA | NA | -6 | -15 | +17 | NA | NA |
| ASDAS | |||||||||||||
| M0 | 4.87 | 3.35 | 3.24 | 3.37 | 5 | 5.36 | 3.8 | 2.98 | 2.68 | 2.41 | 2.94 | 3.2 | 4.12 |
| M3 (change from M0; units) | -1.6 | -0.8 | -0.75 | -0.04 | -1.5 | -1.7 | -0.3 | -0.24 | -1.36 | -0.43 | -0.35 | +0.02 | -1.96 |
| M6 (change from M0; units) | NA | NA | NA | -1.17 | NA | NA | NA | NA | -1.02 | -0.61 | -0.23 | NA | NA |
| BASFI, 0 to 100 | |||||||||||||
| M0 | 86 | 95 | 63 | 32 | 72 | MD | MD | 59.5 | 50 | 57 | 59 | 28 | 36 |
| M3 (change from M0; %) | -8 | -8 | +16 | +3 | +28 | MD | MD | -6 | +6 | -7 | +30 | -29 | +47 |
| M6 (change from M0; %) | NA | NA | NA | +22 | NA | MD | MD | NA | 0 | -7 | -34 | NA | NA |
| Pain VAS, 0 to 10 | |||||||||||||
| M0 | 9 | 10 | 7 | 4 | 7 | 7 | 8 | 4 | 5 | 6 | 5 | 7 | 4 |
| M3 (change from M0; units) | +0.5 | -3 | +1 | 0 | 0 | -0.2 | +1 | +3 | +1 | -2 | 0 | -1 | 0 |
| M6 (change from M0; units) | NA | NA | NA | -1 | NA | NA | NA | NA | +1 | -2 | +2 | NA | NA |
| CRP (mg/dl)a | |||||||||||||
| M0 | 29 | 0 | 2 | 46 | 35 | 96 | 10 | 10.4 | 1 | 1 | 1.8 | 3 | 35.2 |
| M3 (absolute value) | 0.3 | 0 | 0 | NA | 3 | 4 | 1 | < 5 | NA | NA | NA | 3 | 1 |
| M6 (absolute value) | NA | NA | NA | 6 | NA | NA | NA | NA | 0 | 1 | 0.6 | NA | NA |
| ESR (mm)a | |||||||||||||
| M0 | 71 | 9 | 8 | 47 | 35 | 104 | 21 | 12 | 9 | 8 | 1 | 11 | 15 |
| M3 (absolute value) | 10 | 2 | 4 | NA | 2 | 2 | 1 | 3 | NA | NA | NA | 3 | 1 |
| M6 (absolute value) | NA | NA | NA | 5 | NA | NA | NA | NA | 4 | 1 | 1 | NA | NA |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Assessment of SpondyloArthritis International Society-endorsed disease activity score; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; M0, month 0 (baseline); M3, month 3; M6, month 6; MD, missing data; NA, not available; Pt, Patient. aFor CRP and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6).